More than 10,000 drugs have been suspended from the Internet!

The document pointed out that if there is no transaction within one year to suspend listing of drugs (including suspended low-priced drugs), public medical institutions do have purchase needs, and pharmaceutical companies can apply for resumption of listing of the product according to the prescribed procedures before April 30, 2022.

Atorvastatin calcium tablets and other major brands are listed

Taking atorvastatin calcium tablets as an example, this variety occupies a core position in the blood lipid regulator market in China, and it is expected that the total market share of TOP5 products will exceed 80% in 2021

In the centralized procurement and expansion carried out in 2019, Qilu Pharmaceutical, Xin'an Pharmaceutical, and Lepu won the bid for atorvastatin calcium, while the original manufacturer Pfizer did not win the bid

In addition, another blockbuster product of Pfizer, amlodipine besylate tablets (10mg, 10 tablets/box) is also on the list

In the list, there are also children's multi-vitamin chewable tablets (10) (30 tablets/box), acetaminophen oral solution (3.

A number of tinib products were pressed on the pause button

Taking imatinib as an example, the competitive landscape is being reshaped

This year, Xinlitai transferred its imatinib mesylate raw material and its pharmaceutical-related rights and interests to Sinopharm Yixin, and the transfer of technology costs 27 million yuan (tax included)

Lapatinib tosylate tablets and gefitinib also have similar competitive situations.